Actome

Actome is a proteomics company commercializing its innovative PICO technology, which merges immunoassay principles with digital PCR readout to achieve femtomolar sensitivity and absolute quantification of protein targets without reference standards. Its platform aims to displace traditional, cumbersome methods like Western blot, ELISA, and co-immunoprecipitation, particularly in areas such as extracellular vesicle characterization, biomarker detection, and signaling pathway analysis. The company appears to be in an early commercial stage, offering kits and services while engaging in publicly funded research projects to further develop its platform and software analytics.

Protein Interaction Coupling (PICO) technology: an immunoassay that uses antibody-DNA conjugates (PICOglue Labels) and digital PCR readout for absolute, reference-free quantification of proteins, protein interactions, post-translational modifications, and extracellular vesicles. Features include femtomolar sensitivity, wash-free workflow, and multiplexing capability.

Actome competes in the proteomics tools space against established immunoassay giants (e.g., Thermo Fisher, Abcam for ELISA), traditional methods (Western blot, co-IP), and other high-sensitivity platforms like Quanterix's Simoa and Olink's proximity extension assays. Its differentiation lies in claiming absolute quantification without a standard curve and leveraging the precise, digital readout of dPCR.